Effect of transcatheter aortic valve replacement using Venus-A valve for treating patients with severe aortic stenosis

• Published in: Zhōnghuá xīnxuèguănbìng zázhì Vol. 45; no. 10; p. 843
• Main Authors: Song, G Y, Wang, M Y, Wang, Y, Liu, X B, Feng, Y, Kong, X Q, Wu, Y J
• Format: Journal Article
• Language: Chinese
• Published: China 24.10.2017
• Subjects: Aortic Valve; Aortic Valve Stenosis - therapy; Cause of Death; China; Echocardiography; Fluoroscopy; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Prospective Studies; Stroke; Survival Rate; Transcatheter Aortic Valve Replacement - methods; Treatment Outcome; China; Treatment outcome; Transcatheter aortic valve replacement; Aortic valve stenosis
• ISSN: 0253-3758
• DOI: 10.3760/cma.j.issn.0253-3758.2017.10.006

To evaluate the effect of transcatheter aortic valve replacement(TAVR) using Venus-A valve for treating patients with severe aortic stenosis. In this prospective study, 101 consecutive severe aortic stenosis patients with high surgical risk(Society of Thoracic Surgeon(STS) score ≥4%) or at prohibitive surgical risk were enrolled from 5 academic cardiovascular centers in China(Fuwai hospital, the second affiliated hospital of Zhejiang university school of medicine, West China hospital of Sichuan university, the first affiliated hospital of Nanjing medical university, Ruijin hospital of Shanghai Jiaotong university school of medicine) from September 2012 to January 2015, and Venus-A valves were used in TAVR for these patients. The primary endpoints were death from any cause and major stroke in 1 year. The secondary endpoints included efficacy and safety of TAVR in 1 year. TAVR success rate was 97.9%(98/101), and 3 patients were transferred to receive surgical AVR. There were 85 patients using 1 Venus-A valve, a